文献速递妇科产科

塞利尼索联合紫杉醇卡铂治疗晚期卵巢或子宫内膜癌的I期研究

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
PubMed 文献 · Gynecol Oncol · 2020-11-01

最常见治疗相关不良事件为血小板减少(100%)、白细胞减少(91%)和高血糖(87%);结论认为该联合方案安全可耐受。

要点

  • 塞利尼索+CP方案在晚期卵巢癌和子宫内膜癌中安全可耐受
  • 最常见治疗相关不良事件为血小板减少(100%)、白细胞减少(91%)和高血糖(87%)

核心结论

  • 塞利尼索联合卡铂和紫杉醇在晚期卵巢癌和子宫内膜癌中安全且可耐受。

主要发现

  • 最常见治疗相关不良事件为血小板减少(100%)、白细胞减少(91%)和高血糖(87%)。
  • 最常见3/4级治疗相关不良事件为白细胞减少(70%)、中性粒细胞减少(70%)、淋巴细胞减少(61%)、贫血(57%)和丙氨酸转氨酶升高(43%)。
  • 发生1例治疗相关剂量限制性毒性(3级晕厥)。
  • 在卵巢癌和子宫内膜癌中均观察到对全部四种方案的缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Selinexor, a selective inhibitor of nuclear export, monotherapy causes nuclear accumulation of tumor-suppressor proteins and has anti-tumor activity in ovarian and endometrial cancers. The safety and tolerability of oral selinexor plus intravenous carboplatin and paclitaxel chemotherapy (selinexor + CP) was evaluated in this population. PATIENTS AND METHODS: This phase I, 3 + 3 dose-escalation study assessed 4 selinexor + CP regimens. Patients in cohorts of 3, regardless of disease type, were administered 1 of 4 alternating regimens (selinexor at 30 mg/m2 or 60 mg plus CP at AUC 5 and 175 mg/m2 or 80 mg/m2, respectively) for 6-10 cycles (1 cycle = 21 days), followed by selinexor maintenance. Enrolled patients with ovarian cancer had received 1 prior platinum-based therapy. Patients with endometrial cancer were chemotherapy-naive or had received 1 prior platinum-based therapy. Response was evaluated every 9 weeks. RESULTS: Twenty-three patients were treated (5 serous ovarian cancer; 18 endometrial cancer, including 6 carcinosarcomas). The most common treatment-related adverse events (TRAEs) were thrombocytopenia (100%), leukopenia (91%), and hyperglycemia (87%). The most common grade 3/4 TRAEs were leukopenia (70%), neutropenia (70%), lymphopenia (61%), anemia (57%), and alanine transaminase increase (43%). One treatment-related dose-limiting toxicity (grade 3 syncope) occurred. Twelve patients achieved a partial response and 1 achieved a complete response. Responses to all four regimens were observed in ovarian and endometrial cancers. CONCLUSIONS: Combination selinexor + CP was safe and tolerated in advanced ovarian and endometrial cancers.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rubinstein MM, Grisham RN, Cadoo K, et al. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecol Oncol. 2020. PMID: 33139041. doi:10.1016/j.ygyno.2020.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。